

Supplemental Figure 1: Correlation between alemtuzumab levels and CD14/15 chimerism post-HSCT.

Alemtuzumab levels measured at 14 days after transplant were plotted against the CD14/15 chimerism (% donor) measured at 2, 4, 6, 12, and 24 months after transplant for each patient on a scatter plot.

Regression lines are included in each panel. There were no statistically significant correlations.

